We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Roche has partnered with Recursion to generate up to 40 new neuroscience and cancer therapies using the Utah-based biotech firm’s machine-learning drug discovery platform. Read More
In the U.S., an FDA advisory committee narrowly backed authorizing molnupiravir last week, but the agency has yet to approve the COVID-19 pill for emergency use. Read More
Pfizer said Li uploaded over 12,000 documents to her personal drive and devices shortly before she was set to begin working at Xencor, a Monrovia, Calif.-based biotech. Read More
Philip Dormitzer provided Pfizer scientific leadership for the development of the company’s mRNA-based COVID-19 vaccine co-developed with BioNTech. Read More
A federal appeals court has upheld Mylan’s challenge to a Biogen patent covering the latter’s blockbuster multiple sclerosis (MS) drug Tecfidera (dimethyl fumarate). Read More
The new center is located near two large hospitals and a life sciences cluster that, with 400 companies, is the largest in Europe, AstraZeneca said. Read More
GlaxoSmithKline (GSK) has forged an exclusive license agreement with Arrowhead Pharmaceuticals to develop and commercialize ARO-HSD, Arrowhead’s investigational RNA interference (RNAi) therapeutic currently in a phase 1/2 trial. The deal is potentially worth more than $1 billion. Read More
Arcus is now “well-positioned to accelerate and expand clinical development activities … [for] patients with some of the most difficult to treat cancers, including pancreatic, lung, colon and prostate,” said Arcus CEO Terry Rosen. Read More